Kazia Therapeutics (KZIA) Payables (2017 - 2025)

Kazia Therapeutics (KZIA) has disclosed Payables for 6 consecutive years, with $6.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Payables fell 34.93% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Jun 2025, down 34.93%, and an annual FY2025 reading of $6.8 million, down 33.83% over the prior year.
  • Payables was $6.7 million for Q2 2025 at Kazia Therapeutics, down from $10.3 million in the prior quarter.
  • Across five years, Payables topped out at $10.3 million in Q2 2024 and bottomed at $1.2 million in Q2 2023.
  • Average Payables over 4 years is $4.9 million, with a median of $4.1 million recorded in 2022.
  • The sharpest move saw Payables skyrocketed 762.01% in 2024, then plummeted 34.93% in 2025.
  • Year by year, Payables stood at $1.4 million in 2022, then fell by 12.62% to $1.2 million in 2023, then surged by 762.01% to $10.3 million in 2024, then plummeted by 34.93% to $6.7 million in 2025.
  • Business Quant data shows Payables for KZIA at $6.7 million in Q2 2025, $10.3 million in Q2 2024, and $1.2 million in Q2 2023.